ASSET PURCHASE AGREEMENT by and between AstraZeneca AB, Aralez Pharmaceuticals Trading DAC and Aralez Pharmaceuticals Inc. (solely for the purposes of Section 9.16 hereof)Asset Purchase Agreement • October 7th, 2016 • Aralez Pharmaceuticals Inc. • Pharmaceutical preparations • New York
ASSET PURCHASE AGREEMENT (this “Agreement”) is made and executed as of October 3, 2016 (the “Execution Date”), by and between AstraZeneca AB, a Swedish corporation (“Seller”), Aralez Pharmaceuticals Trading DAC, an Irish designated activity company (“Buyer”) and, solely for the purposes of Section 9.16 hereof, Aralez Pharmaceuticals Inc., a corporation organized under the laws of British Columbia, Canada (“Guarantor”). Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO SECOND AMENDED AND RESTATED FACILITY AGREEMENTFacility Agreement • October 7th, 2016 • Aralez Pharmaceuticals Inc. • Pharmaceutical preparations
AMENDMENT TO SECOND AMENDED AND RESTATED FACILITY AGREEMENT (this “Amendment”), dated as of October 3, 2016, by and among ARALEZ PHARMACEUTICALS, INC. (“Parent”), POZEN, INC., TRIBUTE PHARMACEUTICALS CANADA, INC. (“Credit Parties”), DEERFIELD PRIVATE DESIGN FUND III, L.P., DEERFIELD INTERNATIONAL MASTER FUND, L.P., and DEERFIELD PARTNERS, L.P. (collectively referred to as the “Lenders” and together with the Credit Parties, the “Parties”).
October 3, 2016 Aralez Pharmaceuticals Inc.Limited Consent • October 7th, 2016 • Aralez Pharmaceuticals Inc. • Pharmaceutical preparations
